1. Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias.
- Author
-
Marti, Matteo, Rodi, Donata, Qin Li, Guerrini, Remo, Fasano, Stefania, Morella, Ilaria, Tozzi, Alessandro, Brambilla, Riccardo, Calabresi, Paolo, Simonato, Michèle, Bezard, Erwan, and Morari, Michèle
- Subjects
MOVEMENT disorders ,PARKINSON'S disease treatment ,NOCICEPTIN ,NEUROPEPTIDES ,DOPA ,GENE expression ,EXTRACELLULAR signal-regulated kinases ,LABORATORY rodents ,PREVENTION - Abstract
the present study we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogenesis of Parkinson's disease, also affects L-DOPA-induced dyskinesia. In striatal slices of naive rodents, N/OFQ (0.1-1 μM) prevented the increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the Dl receptor agonist SKF38393 in spiny neurons. In vivo, exogenous N/OFQ (0.03-1 nmol, i.c.v.) or a synthetic N/OFQ receptor agonist given systemically (0.01-1 mg/Kg) attenuated dyskinesias expression in 6-hydroxydopamine hemilesioned rats primed with L-DOPA, without causing primary hypoloco-motive effects. Conversely, N/OFQ receptor antagonists worsened dyskinesia expression. In vivo microdialysis revealed that N/OFQ prevented dyskinesias simultaneously with its neurochemical correlates such as the surge of nigral GABA and glutamate, and the reduction of thalamic GABA. Regional microinjections revealed that N/OFQ attenuated dyskinesias more potently and effectively when microinjected in striatum than substantia nigra (SN) reticulata, whereas N/OFQ receptor antagonists were ineffective in striatum but worsened dyskinesias when given in SN. Quantitative autoradiography showed an increase in N/OFQ receptor binding in striatum and a reduction in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ transmission. Finally, the N/OFQ receptor synthetic agonist also reduced dyskinesia expression in l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score. We conclude that N/OFQ receptor agonists may represent a novel strategy to counteract L-DOPA-induced dyskinesias. Their action is possibly mediated by upregulated striatal N/OFQ receptors opposing the Dl receptor-mediated overactivation of the striatonigral direct pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF